Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival.

Afasizheva A, Devine A, Tillman H, Fung KL, Vieira WD, Blehm BH, Kotobuki Y, Busby B, Chen EI, Tanner K.

BMC Cancer. 2016 Mar 5;16:186. doi: 10.1186/s12885-016-2211-7.

2.

Atorvastatin and trans-caryophyllene for the prevention of leukopenia in an experimental chemotherapy model in Wistar rats.

Campos MI, Vieira WD, Campos CN, Aarestrup FM, Aarestrup BJ.

Mol Clin Oncol. 2015 Jul;3(4):825-828. Epub 2015 Apr 9.

3.

NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation.

Namiki T, Yaguchi T, Nakamura K, Valencia JC, Coelho SG, Yin L, Kawaguchi M, Vieira WD, Kaneko Y, Tanemura A, Katayama I, Yokozeki H, Kawakami Y, Hearing VJ.

Cancer Res. 2015 Jul 1;75(13):2708-15. doi: 10.1158/0008-5472.CAN-13-3209. Epub 2015 Apr 1.

4.

AMP kinase-related kinase NUAK2 affects tumor growth, migration, and clinical outcome of human melanoma.

Namiki T, Tanemura A, Valencia JC, Coelho SG, Passeron T, Kawaguchi M, Vieira WD, Ishikawa M, Nishijima W, Izumo T, Kaneko Y, Katayama I, Yamaguchi Y, Yin L, Polley EC, Liu H, Kawakami Y, Eishi Y, Takahashi E, Yokozeki H, Hearing VJ.

Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6597-602. doi: 10.1073/pnas.1007694108. Epub 2011 Apr 1.

5.

Influence of melanosome dynamics on melanoma drug sensitivity.

Chen KG, Leapman RD, Zhang G, Lai B, Valencia JC, Cardarelli CO, Vieira WD, Hearing VJ, Gottesman MM.

J Natl Cancer Inst. 2009 Sep 16;101(18):1259-71. doi: 10.1093/jnci/djp259. Epub 2009 Aug 24.

6.

Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid.

Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, Miyamura Y, Hearing VJ.

J Clin Invest. 2009 Apr;119(4):954-63. doi: 10.1172/JCI34015. Epub 2009 Mar 9.

7.

UV increases the nuclear localization of apurinic/apyrimidinic endonuclease/redox effector factor-1 in human skin.

Takahashi K, Hoashi T, Yamaguchi Y, Mutsuga N, Suzuki I, Vieira WD, Hearing VJ.

J Invest Dermatol. 2006 Dec;126(12):2723-6. Epub 2006 Jun 29. No abstract available.

8.

The repeat domain of the melanosomal matrix protein PMEL17/GP100 is required for the formation of organellar fibers.

Hoashi T, Muller J, Vieira WD, Rouzaud F, Kikuchi K, Tamaki K, Hearing VJ.

J Biol Chem. 2006 Jul 28;281(30):21198-208. Epub 2006 May 8.

9.

SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.

Kimchi-Sarfaty C, Vieira WD, Dodds D, Sherman A, Kreitman RJ, Shinar S, Gottesman MM.

Cancer Gene Ther. 2006 Jul;13(7):648-57. Epub 2006 Feb 24.

10.

Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes.

Valencia JC, Watabe H, Chi A, Rouzaud F, Chen KG, Vieira WD, Takahashi K, Yamaguchi Y, Berens W, Nagashima K, Shabanowitz J, Hunt DF, Appella E, Hearing VJ.

J Cell Sci. 2006 Mar 15;119(Pt 6):1080-91. Epub 2006 Feb 21.

11.

Mutations in dopachrome tautomerase (Dct) affect eumelanin/pheomelanin synthesis, but do not affect intracellular trafficking of the mutant protein.

Costin GE, Valencia JC, Wakamatsu K, Ito S, Solano F, Milac AL, Vieira WD, Yamaguchi Y, Rouzaud F, Petrescu AJ, Lamoreux ML, Hearing VJ.

Biochem J. 2005 Oct 15;391(Pt 2):249-59.

12.

MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes.

Hoashi T, Watabe H, Muller J, Yamaguchi Y, Vieira WD, Hearing VJ.

J Biol Chem. 2005 Apr 8;280(14):14006-16. Epub 2005 Jan 28.

13.

Immortalization of mouse melanocytes carrying mutations in various pigmentation genes.

Costin GE, Vieira WD, Valencia JC, Rouzaud F, Lamoreux ML, Hearing VJ.

Anal Biochem. 2004 Dec 1;335(1):171-4. No abstract available.

PMID:
15519586
14.

Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity.

Watabe H, Valencia JC, Yasumoto K, Kushimoto T, Ando H, Muller J, Vieira WD, Mizoguchi M, Appella E, Hearing VJ.

J Biol Chem. 2004 Feb 27;279(9):7971-81. Epub 2003 Nov 21.

15.
16.

The Seiji memorial lecture: the melanosome: an ideal model to study cellular differentiation.

Kushimoto T, Valencia JC, Costin GE, Toyofuku K, Watabe H, Yasumoto K, Rouzaud F, Vieira WD, Hearing VJ.

Pigment Cell Res. 2003 Jun;16(3):237-44.

PMID:
12753396
17.

Proteomic analysis of early melanosomes: identification of novel melanosomal proteins.

Basrur V, Yang F, Kushimoto T, Higashimoto Y, Yasumoto K, Valencia J, Muller J, Vieira WD, Watabe H, Shabanowitz J, Hearing VJ, Hunt DF, Appella E.

J Proteome Res. 2003 Jan-Feb;2(1):69-79.

PMID:
12643545
19.
20.

A melanocyte-keratinocyte coculture model to assess regulators of pigmentation in vitro.

Lei TC, Virador VM, Vieira WD, Hearing VJ.

Anal Biochem. 2002 Jun 15;305(2):260-8.

PMID:
12054455
21.

The etiology of oculocutaneous albinism (OCA) type II: the pink protein modulates the processing and transport of tyrosinase.

Toyofuku K, Valencia JC, Kushimoto T, Costin GE, Virador VM, Vieira WD, Ferrans VJ, Hearing VJ.

Pigment Cell Res. 2002 Jun;15(3):217-24. Erratum in: Pigment Cell Res. 2002 Oct;15(5):400..

PMID:
12028586
22.

Production of melanocyte-specific antibodies to human melanosomal proteins: expression patterns in normal human skin and in cutaneous pigmented lesions.

Virador V, Matsunaga N, Matsunaga J, Valencia J, Oldham RJ, Kameyama K, Peck GL, Ferrans VJ, Vieira WD, Abdel-Malek ZA, Hearing VJ.

Pigment Cell Res. 2001 Aug;14(4):289-97.

PMID:
11549113
23.

A model for melanosome biogenesis based on the purification and analysis of early melanosomes.

Kushimoto T, Basrur V, Valencia J, Matsunaga J, Vieira WD, Ferrans VJ, Muller J, Appella E, Hearing VJ.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10698-703. Epub 2001 Aug 28.

24.

An episomally maintained MDR1 gene for gene therapy.

Lee CG, Vieira WD, Pastan I, Gottesman MM.

Hum Gene Ther. 2001 May 20;12(8):945-53.

PMID:
11387059
25.

In situ localization of agouti signal protein in murine skin using immunohistochemistry with an ASP-specific antibody.

Matsunaga N, Virador V, Santis C, Vieira WD, Furumura M, Matsunaga J, Kobayashi N, Hearing VJ.

Biochem Biophys Res Commun. 2000 Apr 2;270(1):176-82.

PMID:
10733924
26.
27.

Retroviral transfer of human MDR1 gene to hematopoietic cells: effects of drug selection and of transcript splicing on expression of encoded P-glycoprotein.

Licht T, Aran JM, Goldenberg SK, Vieira WD, Gottesman MM, Pastan I.

Hum Gene Ther. 1999 Sep 1;10(13):2173-85.

PMID:
10498249
28.

Characterization of genes modulated during pheomelanogenesis using differential display.

Furumura M, Sakai C, Potterf SB, Vieira WD, Barsh GS, Hearing VJ.

Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7374-8.

29.

Modulation of murine melanocyte function in vitro by agouti signal protein.

Sakai C, Ollmann M, Kobayashi T, Abdel-Malek Z, Muller J, Vieira WD, Imokawa G, Barsh GS, Hearing VJ.

EMBO J. 1997 Jun 16;16(12):3544-52.

30.

Studies on the expression and immunogenicity of the B50 melanoma antigen and its relationship with calreticulin.

Bijwaard K, Hearing VJ, Sontheimer R, Lieu TS, Vieira WD, Gersten DM.

Melanoma Res. 1995 Oct;5(5):327-36.

PMID:
8541723
31.

Modulation of melanogenic protein expression during the switch from eu- to pheomelanogenesis.

Kobayashi T, Vieira WD, Potterf B, Sakai C, Imokawa G, Hearing VJ.

J Cell Sci. 1995 Jun;108 ( Pt 6):2301-9.

32.

Further studies of the therapeutic effects of murine melanoma-specific monoclonal antibodies.

Law LW, Vieira WD, Hearing VJ, Gersten DM.

Biochim Biophys Acta. 1994 Apr 12;1226(1):105-9.

PMID:
7908833
33.

Production of monoclonal antibodies against the B700 murine melanoma antigen and their antimetastatic properties.

Gersten DM, Moody D, Vieira WD, Law LW, Hearing VJ.

Biochim Biophys Acta. 1992 Feb 14;1138(2):109-14.

PMID:
1540656
34.
35.

Suppression of established pulmonary metastases by murine melanoma-specific monoclonal antibodies.

Hearing VJ, Leong SP, Vieira WD, Law LW.

Int J Cancer. 1991 Jan 2;47(1):148-53.

PMID:
1985871
36.

Differentiation and the tumorigenic and metastatic phenotype of murine melanoma cells.

Kameyama K, Vieira WD, Tsukamoto K, Law LW, Hearing VJ.

Int J Cancer. 1990 Jun 15;45(6):1151-8.

PMID:
2161802
37.

JB/MS murine melanoma: a new model for studies on the modulation of differentiation and of tumorigenic and metastatic potential.

Hearing VJ, Cannon GB, Vieira WD, Jiménez-Atiénzar M, Kameyama K, Law LW.

Int J Cancer. 1988 Feb 15;41(2):275-82.

PMID:
2828247
38.

A unique tumor rejection antigen from the S91 murine malignant melanoma.

Law LW, Vieira WD, Kameyama K, Hearing VJ.

Cancer Res. 1987 Nov 15;47(22):5841-5.

39.

Murine melanoma-specific tumor rejection activity elicited by a purified, melanoma-associated antigen.

Hearing VJ, Gersten DM, Montague PM, Vieira WD, Galetto G, Law LW.

J Immunol. 1986 Jul 1;137(1):379-84.

PMID:
3711669
40.

Malignant melanoma: cross-reacting (common) tumor rejection antigens.

Hearing VJ, Vieira WD, Law LW.

Int J Cancer. 1985 Mar 15;35(3):403-9.

PMID:
2579039
41.

The effect of immunopharmacological agents on mouse natural cell-mediated cytotoxicity and on its augmentation by poly I:C.

Djeu JY, Heinbaugh JA, Vieira WD, Holden HT, Herberman RB.

Immunopharmacology. 1979 Jun;1(3):231-44.

PMID:
262451

Supplemental Content

Loading ...
Support Center